



UPDATE IN INTENSIVE CARE MEDICINE: SEVERE INFECTIONS DUE TO MULTI-RESISTANT GRAM-NEGATIVE BACILLI

Antibiotics in development for multiresistant gram-negative bacilli



A. Rodríguez^{a,b,*}, G. Moreno^a, M. Bodi^{a,b}, I. Martín-Loeches^c

^a Servicio de Medicina Intensiva, Hospital Universitario Joan XXIII, Tarragona, Spain

^b IISPV/CIBERES, Tarragona, Spain

^c Trinity College Dublin, School of Medicine, Intensive Care Medicine St James's Hospital, Dublin, Ireland

Received 6 February 2022; accepted 26 May 2022

Available online 24 October 2022

KEYWORDS

New antibiotics;
Multiresistant gram
negative bacilli;
Beta-lactamases;
Metallo-beta-
lactamases

Abstract The rapid increase in antibiotic (ATB) resistance among Gram-negative bacilli (BGN), especially in strains of Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, with high resistance patterns (XDR), poses a huge threat to health systems worldwide.

In the last decade, different ATBs have been developed against XDR, some of which combine a lactam β along with a β -lactamase inhibitor, while others use non- β -lactam inhibitors. Most of them have adequate “in vitro” activity on several β -lactamases of class A, C and D of Ambler. However, combinations such as Ceftazidime/avibactam, Ceftolozane/Tazobactam and Meropenem/vaborbactam have no activity against metallo- β -lactamases (M β L). New combinations such as Aztreonam/AVI, Cefepime/Zidebactam, or new cephalosporins such as Cefiderocol, have efficacy against M β L enzymes. Although some of these combinations are already approved and in the commercialization phase, many of them have yet to define their place within the treatment of microorganisms with high resistance through clinical studies.

© 2022 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

PALABRAS CLAVE

Nuevos antibióticos;
Bacilos gram
negativos
multirresistentes;
Beta-lactamasas;
Metallo-beta-
lactamasas

Antibióticos en desarrollo para bacilos gram negativos multirresistentes

Resumen El rápido incremento en las resistentes a los antibióticos (ATB) entre los bacilos Gram negativos (BGN), especialmente en cepas de Enterobacterias, *P. aeruginosa*, y *A. baumannii*, con elevadas elevados patrones de resistencia (XDR), plantea una enorme amenaza para los sistemas de salud en todo el mundo.

En la última década, diferentes ATB han sido desarrollados contra XDR, algunos de los cuales combinan un β -lactámico junto con un inhibidor de β -lactamasas, mientras que otros utilizan inhibidores no β -lactámicos. La mayoría de ellos presenta una adecuada actividad “in

* Corresponding author.

E-mail address: ahr1161@yahoo.es (A. Rodríguez).

vitro” sobre varias β -lactamasas de clase A, C y D de Ambler. Sin embargo, combinaciones como Ceftazidime/avibactam, Ceftolozano/Tazobactam y Meropenem/vaborbactam no presentan actividad contra metalo- β -lactamasas (M β L). Nuevas combinaciones como Aztreonam/AVI, Cefepime/Zidebactam, o modernas cefalosporinas como Cefiderocol, presentan eficacia contra casi la totalidad de las M β L. Aunque algunas de estas combinaciones ya están aprobadas y en fase de comercialización, muchas de ellas aún deben definir su lugar dentro del tratamiento de microorganismos con resistencia elevada a través de estudios clínicos.

© 2022 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

Introduction

Antimicrobial resistance is a reality and a constant concern for healthcare professionals, given the lack of availability of new molecules to treat highly resistant microorganisms.^{1–3} This problem has been exacerbated by the virulent pandemic caused by severe acute respiratory syndrome due to coronavirus type 2, resulting in COVID-19, which has, at the time of writing this review, caused more than 350 million infections, with just over 5 million deaths worldwide. This situation has not only created a crisis in the global healthcare system, but has also led to an uncontrolled increase in superinfections in patients with COVID-19, with a high and possible excessive use of antibiotics (ATB). According to data from the ENVIN-HELICS registry (<https://hws.vhebron.net/envin-helics/>), the incidence density of ventilator-associated pneumonia (VAP) rose from just over 5 episodes/1000 mechanical ventilation (MV) days in 2019 to 11.5 episodes/1000 MV days during the pandemic (2020), while ATB use in intensive care unit (ICU) patients grew from 61% (2019) to more than 90% during the pandemic (2020). At the same time, the isolation of multidrug-resistant gram-negative bacilli (GNB) was up by just over 40% overall, but if carbapenemase-positive GNB are considered, the observed incidence doubled with respect to 2019 from 0.8% to 1.66% overall and, especially, the acquisition of these microorganisms in the ICU tripled, from 0.35% to 1.33% in 2020.

Although the definition of bacterial resistance has been modified in recent years, we can assume that three types of microbial resistance are defined: 1) *multidrug-resistant* (MDR), defined as resistance to at least one agent in three or more ATB families; 2) *extensive drugs resistance* (XDR), defined as resistance to at least one ATB in all but one or two of the families, and 3) *pan-drug resistance* (PDR), defined as resistance to all ATBs. Recently, a new category called *difficult-to-treat resistance* (DTR) has been recognised, defined as high resistance to first-line ATBs.^{4,5} Semantic issues aside, infections caused by resistant microorganisms are associated with diminished quality of life, increased health costs, the need for more expensive ATBs or the reuse of «old» ATBs having a high-toxicity profile, and, of course, increased mortality.^{6,7}

To complicate the picture even further, development programmes for new ATB agents are conditioned by a strong disincentive for companies, as the return on investment

in ATB development is significantly lower than for other drugs for chronic diseases or cancer.^{8,9} If one considers the observed mortality and treatment-related economic impact, the group of micro-organisms called «ES[KC]APE» (E: *Enterococcus faecium*; S: *Staphylococcus aureus* or also *Stenotrophomonas maltophilia*; K: *Klebsiella pneumoniae*, or, recently, C: *Clostridioides difficile*; A: *Acinetobacter baumannii*; P: *Pseudomonas aeruginosa*; E: *Enterobacter* spp or recently *Enterobacteriaceae*) pose the most formidable clinical challenge today.^{10,11} To counter this adverse scenario, the European Federation of Pharmaceutical Industries and Associations partnered with the European Union to establish the largest public-private partnership for the development of the Innovative Medicines Initiative under the New Drugs for Bad Bugs programme, which encourages everything from new antibiotic development and clinical research to the reshaping of antibiotic use, in the hope of catalysing the approval of new antibiotics.¹²

The aim of this review is to gain insight into clinically relevant aspects of new ATBs and their combinations for the treatment of resistant GNBs. To this end, a Pubmed/Medline search was conducted from 2012 to 2021 using the keywords: *intensive care, critical care, nosocomial pneumonia, hospital-acquired pneumonia, healthcare-associated/acquired pneumonia, ventilator-acquired pneumonia*, in combination with *novel antibiotics/antimicrobials, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, cefepime/zidebactam, aztreonem/avibactam, cefiderocol*. The review includes the results of randomised studies, meta-analyses, high-quality observational studies, systematic or narrative reviews, international guidelines, and expert opinions. Due to the limited scope of this review, not all ATBs in the pipeline can be included; consequently, those marketed or close to approval and with special indication in respiratory infection have been chosen.

B-Lactams + β -lactamase inhibitor

Ceftazidime/avibactam (CAZ/AVI)

CAZ is a third-generation cephalosporin with activity against *Pseudomonas* spp. combined with a semisynthetic non- β -lactam β -lactamase inhibitor (AVI), which has already been marketed and approved for the treatment of severe

| Betalactamases | CTZ/ TAZ | CAZ/ AVI | MERO/ VABO | IMI/CIL/ REL | AZT/ AVI | CFP/ ZDB | CFP/ TBB | CFP/ ETZ | MERO/ NACU | CFD |
|---|----------------|----------------|---------------|-----------------|------------------|-------------|-------------|----------------|---------------|-----|
| Class A, including BLEE (CTM-X,SHV, TEM, SHV, etc.) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Class A carbapenemases (KPC, etc.) | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Class B metalloβ-lactamases (VIM,NDM,IMP, etc.) | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✗ | ✓ | ✓ |
| Class C cephalosporinases (AmpC, etc.) | ✓ ¹ | ✓ ² | ✓ | ✓ | ✓ ^{1,2} | ✓ | ✓ | ✓ ² | ✓ | ✓ |
| Class D oxacillinase (OXA-48) | ✗ | ✓ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Class D oxacyclases (OXA-23,OXA-24, OXA-58, etc.) | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

Figure 1 Action of new antimicrobials on different beta-lactamases alone or in combination.

X not active, ✓ active. Variable activity: 1 for *P. aeruginosa*, 2 for Enterobacteriaceae.

ATZ/AVI: aztreonam/avibactam; CAZ/AVI: ceftazidime/avibactam; CFD: ceftiderocol; CFP/TBB: ceftopime/taniborbactam; CFP/ETZ: ceftopime/enmetazobactam; CFP/ZDB: ceftopime/zidebactam; CTZ/TAZ: ceftolozane/tazobactam; IMI/CIL/REL: Imipenem/cilastatin/relebactam; MERO/NACU: meropenem/nacubactam; MERO/VABO: meropenem/vaborbactam.

GNB infections.¹³ The combination with AVI restores the effectiveness of CAZ on β -lactamase-producing bacteria (BLEE, AmpC, and CPE), such as *Enterobacteriaceae* and *Pseudomonas aeruginosa* (Fig. 1). AVI, together with CAZ, reduces the minimum inhibitory concentration (MIC₅₀ and MIC₉₀) against *P. aeruginosa*, possibly due to inactivation of AmpC. However, the additional resistance mechanisms that *Pseudomonas* spp. present, such as alterations of porins, metallo- β -lactamases (MBL), efflux pumps, and OXA β -lactamases, among others, mean that the effectiveness of this ATB is more evident in enterobacteria. CAZ/AVI demonstrates high efficacy against MDR and XDR enterobacteria compared to its comparators, such as meropenem (MERO) or piperacillin/tazobactam (PTZ).¹⁴ In a recent systematic review by Soriano et al.¹⁵ involving 1926 patients treated with CAZ/AVI (alone or in combination) and 1114 patients as comparators/controls, the authors observed a favourable outcome associated with CAZ/AVI in patients with severe GNB infections. The most common infections reported among the infected participants were pneumonia, bacteraemia, and skin and soft tissue infection (SSTI). It is interesting to note that 1718 Enterobacteriaceae exhibited carbapenem resistance or carbapenemase production and 150 *P. aeruginosa* had MDR and XDR among the patients treated. Most of the publications included in the review reported a more favourable outcome for CAZ/AVI (clinical cure between 45% to 100%) and statistically superior to comparator ATBs. On the other hand, the authors point out that resistance was uncommon, and generally in carbapenemase-producing *Klebsiella pneumoniae* (KPC). The authors conclude that the review provides evidence of sufficient quality to support the use of CAZ/AVI in the treatment of hospitalised patients with carbapenemase-producing Enterobacteriaceae and MDR *P. aeruginosa*.

In summary, CAZ/AVI inhibits Ambler class A and C β -lactamases and some class D enzymes, including broad-spectrum β -lactamases (BLEE), KPC and OXA-48 carbapenemases, and AmpC enzymes. CAZ/AVI does not inhibit class B enzymes (metallo- β -lactamases) and fails to inhibit many class D enzymes. Table 1 provides comparative characteristics between CAZ/AVI and other combinations.

Ceftolozane/tazobactam (CTZ/TAZ)

CTZ is another broad-spectrum cephalosporin already commercially available and administered in combination with a β -lactamase inhibitor (TAZ). CTZ differs from other cephalosporins by its 3- and 7-position side chains with a bicyclic β -lactam/dihydrothiazine ring. The 7-position ring provides activity against GNB, while the 3-position ring increases stability against AmpC and prevents hydrolysis by microorganisms such as *P. aeruginosa*.¹⁶ The combination with TAZ decreases the MIC₅₀₋₉₀ of microorganisms producing class A and C β -lactamases such as *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* spp., and *Serratia* spp. and achieves its activity by irreversibly binding to β -lactamases and undergoing slow hydrolysis. Narrow-spectrum β -lactamases such as TEM-1, TEM-2, SHC-1, and OXA-1 have little effect on CTZ/TAZ activity (Fig. 1). Conversely, BLEE, TEM3-9, SHV-2-4, OXA-2, and CTX-M-3-18 reduce the drug's activity; however, it may still remain effective. In a review of phase III studies of CTZ/TAZ in complicated urinary tract infection and intra-abdominal infection (IIA) caused by BLEE-producing *E. coli* and *K. pneumoniae*, 82% of the 159 pathogens were found to be susceptible and 97.4% were clinically cured.¹⁷

CTZ/TAZ maintains its activity against efflux pump-producing bacteria (MexXY, MexAB), in addition to having been found to maintain its activity against several strains of *P. aeruginosa* with PDR, XDR, and MDR resistance profiles that modify their PBP (penicillin-binding proteins).¹⁶⁻¹⁸ However, CTZ/TAZ has no activity against carbapenemases or metallo- β -lactamases, nor does it show any activity against *Stenotrophomonas* spp. and *Acinetobacter* spp. (Fig. 1). The pivotal study on the use of CTZ/TAZ in nosocomial pneumonia including VAP¹⁹ concluded that it was non-inferior to the comparator (MERO) in a subgroup of patients who could have a better outcome, particularly in the presence of MDR and XDR *P. aeruginosa*, which is why high-dose CTZ/TAZ is currently a treatment option for VAP caused by resistant micro-organisms, especially *P. aeruginosa*, which is why in a recent review on the treatment of nosocomial pneumonia²⁰ in a recent expert consensus,²⁰ CTZ/TAZ was included as the

Table 1 Distinguishing characteristics of the main combinations on the market.

| Characteristics | CAZ/AVI | CTZ/TAZ | MERO/VABO | IMI/CIL/REL | CFD |
|--|---|--|--|--|--------------------------------------|
| Half-life (h) | 1.5–3.0 | 1.0–2.6 | 1.0–1.9 | 1.1–1.8 | 2–2.7 |
| Protein binding (%) | 5–22 | 16–30 | 2–33 | 20–22 | 58 |
| Distribution volume (l) | 19–28 | 12–19 | 19–29 | 19–22 | 16 |
| Lung penetration (AUC ELF/AUC plasma) | 0.31/0.35 | 0.44–0.48 | 0.58–0.3 | 0.43–0.44 | 0.1 |
| Elimination | Renal | Renal | Renal | Renal | Renal |
| Indications | | | | | |
| GNB with limited treatment options | Yes | No | Yes | Yes | Yes |
| Complicated IIA | Yes | Yes | Yes | Yes | No |
| NP | Yes | Yes | Yes | Yes | Yes |
| Secondary bacteraemia | Yes | No | Yes | Yes | No |
| Administration | 2 g/0.5 g every 8 h | 2 g/1 g every 8 h | 2 g/2 g every 8 h | 0.5 g/0.5 g/0.25 every 6 h | 2 g every 8 h |
| Duration of infusion (h) | 2 | 1 | 3 | 1 | 3 |
| Adjustment for hyperfiltering renal function | No | No | No | No | Yes (>120) 2 g every 6 h |
| Adjustment for AKI (CrCL cut-off in mL/min) | Yes (<50) | Yes (<50) | Yes (>40) | Yes (<90) | Yes (<90) |
| | 30–50 = 1 g/0.25 g every 8 h ^b | 30–50 = 1 g/0.5 g every 8 h ^a | 39–20 = 1 g/1 g every 8 h ^c | 90–60 = 400/400/200 every 6 h ^d | 90–60 = 2 g every 8 h ^e |
| | 15–29 = 0.75 g/0.1875 g every 12 h ^b | 15–29 = 0.5 g/0.25 g every 8 h ^a | 10–19 = 1 g/1 g every 12 h ^c | 59–30 = 300/300/150 every 6 h ^d | 59–30 = 1.5 g every 8 h ^e |
| | HD = 0.75 g/0.1875 g every 24–48 h ^b | HD = 1.5 g/0.75 g loading ^a + 300 mg/150 mg every 8 h post-HD | HD = 0.5 g/0.5 g every 12 h ^c | 29–15 = 200/200/100 every 6 h ^d | 29–15 = 1 g every 8 h ^e |
| | | | | DH = 200/200/100 post-HD ^d | HD = 0.75 g every 12 h ^e |
| Adjustment for liver disease | No | No | No | No | No |

CAZ/AVI: ceftazidime/avibactam; CFD: cefiderocol; CTZ/TAZ: ceftolozane/tazobactam; IMI/CLI/REL: imipenem/cilastatin/relebactam; MERO/VABO: meropenem/vaborbactam.

^a Recommended dose for pneumonia: https://cima.aemps.es/cima/dochtml/ft/1151032001/FT_1151032001.html.

^b Recommended dosis: https://cima.aemps.es/cima/dochtml/ft/1161109001/FT_1161109001.html.

^c Recommended dosis: https://cima.aemps.es/cima/dochtml/ft/1181334001/FT_1181334001.html.

^d Recommended dosis: https://cima.aemps.es/cima/dochtml/ft/1191420001/FT_1191420001.html.

^e Recommended dosis: https://cima.aemps.es/cima/pdfs/ft/1201434/FT_1201434.pdf.

first treatment option for VAP with high risk of *P. aeruginosa* having any kind of resistance profile in the «PANNUCI» algorithm. The differential characteristics between CTZ/TAZ and other modern combinations can be found in Table 1.

It is important to emphasise that, despite the fact that unlike other cephalosporins, CTZ/TAZ has demonstrated great stability against AmpC, the clinical use of this agent has revealed the emergence of resistance during treatment related to AmpC mutations.^{21–23} The rate of resistance to CTZ/TAZ during administration varies from 3% to 14% and development of resistance during treatment is expected to occur most likely in MDR and XDR isolates, many of which already have one of the required mutations (leading to overexpression of AmpC). When this CTZ/TAZ resistance emerges, susceptibility is generally restored to meropenem and PTZ, which can then be used in treatment.²¹

Carbapenem + β -lactamase inhibitor

Meropenem/vaborbactam (MERO/VABO)

The development of new combinations based on «old» carbapenemics, together with new β -lactamase inhibitors that are active on carbapenemases, is one of the most promising strategies to treat carbapenem-resistant Enterobacteriaceae (CRE).

MERO/VABO is the combination of a Group 2 carbapenem (MERO) with a new β -lactamase inhibitor based on cyclic boronic acid (VABO) approved and marketed to treat complicated UTI, intra-abdominal infection, and nosocomial pneumonia, including VAP caused by GNB with limited treatment options. VABO, thanks to its β -lactamase inhibition profile, increases the spectrum of MERO activity to strains of enterobacteria that produce KPC-type carbapenemases and class A carbapenemases.^{24,25} These enterobacterial strains are typically resistant to other carbapenems, other β -lactams and, in addition, may be resistant to non- β -lactam ATBs due to chromosomal mutations and plasmids.²⁶ Several publications have reported MERO/VABO activity against KPC-producing Enterobacteriaceae to exceed 99%.^{24,26,27} MERO/VABO is also active against KPC mutant strains, which are resistant to CAZ/AVI (KPC-8, KPC-31) and is capable of decreasing the MIC of strains with diminished susceptibility to MERO due to BLEE or AmpC production (Fig. 1). On the other hand, MERO/VABO is not effective against class B and D carbapenemases. Unfortunately, MERO/VABO activity against *Pseudomonas aeruginosa* and *Acinetobacter* spp. is similar to MERO alone; this is because resistance to MERO is mediated by mechanisms that are not affected by VABO, such as membrane permeability, efflux pump dysregulation, and class B and D β -lactamase production.

The second randomised phase III study (TANGO II),²⁸ which evaluated the effectiveness of MERO/VABO relative to the best available therapy (BAT) in patients with various serious infections (including VAP) with suspected carbapenem-resistant Enterobacteriaceae, was terminated prematurely for ethical reasons of efficacy after enrolling only 77 patients. Despite this significantly decreasing the power of the study, an improvement in clinical (59% vs. 26%) and microbiological (65% vs. 40%) cure was observed for patients treated with MERO/VABO over MTD. Specifi-

cally, in the VAP subgroup, there was a significant reduction in 28-day mortality (22% vs. 44%) compared to BAT. Even with its limitations regarding the power of the study, TANGO II suggests that MERO/VABO is a suitable treatment option for carbapenemase-producing Enterobacteriaceae. Table 1 illustrates the differential characteristics of MERO/VABO compared to other new combinations.

Imipenem/relebactam/cilastatin (IMI/REL/CIL)

IMI/REL/CIL is a combination of a classical carbapenem (IMI), together with a renal dehydropeptidase-I inhibitor (CIL) and a modern β -lactamase inhibitor (REL), which has recently been approved in the European Union for the treatment of nosocomial pneumonia, VAP, complicated UTIs, and ARI in adults with limited treatment alternatives.^{29,30}

REL inhibits class A and C β -lactamases, as well as cephalosporinases produced by *Pseudomonas* spp. However, REL is not active on class B MBL or class D β -lactamases (Fig. 1).

The addition of REL leads to a marked decrease in the MIC₅₀₋₉₀ of IMI on BLEE- and KPC-producing enterobacteria, as well as on IMI-resistant strains of *P. aeruginosa*.^{29,31,32} In addition, neither IMI nor REL is subject to bacterial efflux mechanisms; this feature affords it a comparative advantage over other ATBs that are affected by strains expressing efflux pumps.^{29,32}

Although the *in vitro* activity profile of IMI/CIL/REL on carbapenem-resistant *P. aeruginosa* strains is similar to CAZ/AVI, IMI/CIL/REL maintains high activity against *P. aeruginosa* that develop resistance to CAZ/AVI and CTZ/TAZ,³³ making it a suitable choice for rescue therapy in severe infections.

IMI/CIL/REL was non-inferior to the comparator PTZ for the primary endpoint of 28-day, all-cause mortality in the randomised RESTORE-IMI 2³⁴ study. However, in the pre-defined subgroup analysis of patients with MV or APACHE II of more than 15 points, IMI/CIL/REL presented lower mortality than the comparator.

Although not yet commercialised in our country, the positioning of this combination has yet to be determined with respect to other available therapeutic options with similar characteristics (Table 1); the available evidence suggests that IMI/CIL/REL is an appropriate and well-tolerated treatment option for severe patients (APACHE > 15) or in MV affected by severe infections caused by carbapenem-resistant GNB.

Meropenem/nacubactam (MERO/NACU)

NACU is a non- β -lactam β -lactamase inhibitor that is administered together with MERO for the treatment of GNB infections. NACU has proven to be active against class A and C β -lactamases and, to a lesser extent, against class D β -lactamases.^{35,36}

On its own, NACU possesses antibacterial activity by binding to PBP2 of several enterobacteria; therefore, when administered in combination with MERO, its effectiveness is increased by binding to other PBPs. This efficacy is observed on BLEE-, AmpC-, KPC-, MBL-, and OXA-48-producing enterobacteria, as well as on AmpC-producing *P. aeruginosa*

strains (derepressed) or BLEE class A type PER or VEB^{37,38} (Fig. 1). The PK profile of NACU is similar to other inhibitors and the plasma concentration and cumulative urinary excretion is similar to MERO; consequently, MERO/NACU dosing in renal dysfunction is consistent with that established for administration of MERO on its own. These properties make MERO/NACU an outstanding candidate for future clinical research with intractable microorganisms.

Monobactam + β -lactamase inhibitor

Aztreonem/avibactam (AZT/AVI)

AZT is a classic single-ring (monobactam) β -lactam ATB, active against aerobic GNBs, but inactive against gram-positive microorganisms. Its use has been extremely limited in the past due to the high prevalence of BLEE- and AmpC-producing microorganisms. In contrast, MBLs that hydrolyse all β -lactams do not affect monobactams, such as ATZ and this feature has allowed them to be used in certain MBL-producing strains.^{39,40} However, given that other factors of resistance, such as the class A β -lactamase or AmpC are often present, ATZ can only be used in one out of three subjects with MBL. The addition of AVI, a previously described non- β -lactam β -lactamase inhibitor, restores AZT's ability to work with MBL-expressing strains, such as VIM (*Verona-integron-encoded BML*), imipenemases (IMPase), and NDM (*New Delhi MBL*), along with KPC or other OXA-type carbapenemases.⁴¹ ATZ/AVI was more active than MERO, amikacin, and CAZ/AVI in almost completely inhibiting enterobacterial strains with dual carbapenemase production (Fig. 1). However, another study revealed that AZT/AVI was active for all carbapenemase-producing GNB strains, with the exception of NDM-1 and NDM-7 produced by *E. coli* strains from Singapore.^{41–44} Its spectrum over all classes of β -lactamases establishes AZT/AVI as a priority in ICUs with high MBL. The appropriate dose in renal dysfunction has yet to be elucidated. Several phase I studies (<https://www.withpower.com/trial/phase-1-Renal-Insufficiency-7-2020-bffb2>/<https://www.clincosm.com/trial/renal-insufficiency-saint-paul-aztreonam-avibactam>) may be capable of yielding this information in the near future.

Cephalosporins/ β -lactamase inhibitor

Cefepime/zidebactam (CFP/ZDB)

CFP is a well-known fourth-generation cephalosporin that acts by binding to PBP3 and also to PBP1 of gram-positive and gram-negative microorganisms, including *P. aeruginosa*. AmpC has low affinity for CFP; thus, CFP remains active against enterobacteria with derepressed AmpC. However, CFP can be hydrolysed by some class A β -lactamases, including BLEE, KPC, as well as MBL (class B), in addition to some class D β -lactamases (OXA).⁴⁵

ZDB is a non- β -lactam ATB with a dual mode of action, involving high and selective affinity for PBP 2 of GNB and inhibition of β -lactamases.^{46,47} ZDB lends CFP great potential for action against carbapenemase-producing

Enterobacteriaceae, *P. aeruginosa*, and MDR *Acinetobacter baumannii*, and for those strains of *P. aeruginosa* that exhibit multiple resistance mechanisms, including the combination of efflux pump stimulation with porin depletion or overproduction of AmpC^{45,48,49} (Fig. 1). Of particular importance is the marked effect on class D carbapenemase-producing strains and on MBL-producing strains, including VIM, IMP, and NDM, as well as on *P. aeruginosa* overexpressing AmpC and MBL (VIM and IMI).⁵⁰

The positioning of CFP/ZDB has yet to be determined with data on clinical use; it will therefore depend on the assigned cut-off point for comparison with other modern ATBs. Until then, and based on *in vitro* results, it could play a key role in the treatment of patients with MDR enterobacteria and BLEE- and MBL-producing *P. aeruginosa*.⁵¹

Cefepime/taniborbactam (CFP/TBB)

TBB is a new β -lactamase inhibitor based on cyclic boronate that lacks antibacterial activity, but is a potent *in vitro* inhibitor of BLEE and MBL activity.⁴⁸ TBB imparts CFP with activity against intractable microorganisms including Enterobacteriaceae and MERO-resistant *P. aeruginosa*, BLEE-producers, AmpC, OXA, KPCs, and MBLs including VIM and NDM^{52–54} (Fig. 1). Although its *in vitro* effect is very compelling, clinical studies (CERTAIN-1 in UTI and CERTAIN-2 in VAP) have yet to be undertaken, after which TBB should be positioned with regard to modern MBL inhibitors.

Cefepime/enmetazobactam (CFP/ETZ)

ETZ is a penicillanic acid sulphone and a modern β -lactamase inhibitor, especially against BLEE (TEM, SHV, CTX). Combination with CFP provides *in vitro* activity comparable to MERO, but superior to PTZ against BLEE-producing enterobacteria.^{55,56} *In vitro* studies also demonstrate that CFP/ETZ is effective against strains of enterobacteria producing class A, C, and D β -lactamases^{57,58} (Fig. 1). Clinical data on its effectiveness in VAP compared to other new combinations are still needed to position it clinically.

New cephalosporins

Cefiderocol (CFD)

CFD is a new siderophore cephalosporin that has been commercialised since 2020 with a dual mechanism of action; in addition to the passive diffusion of CFD through outer membrane porin channels, CFD can bind extracellular free iron through its siderophore side chain. Bacteria naturally secrete siderophores to allow ferric iron to be absorbed from the host environment; as a result, CFD binds to free ferric iron and, therefore, uses the bacterial uptake of siderophores to penetrate the bacterium, a mechanism known as the «Trojan horse».^{59,60} On the other hand, CFD binds to PFP, especially PFP3, inhibiting the synthesis of the bacterial peptidoglycan cell wall, resulting in lysis and cell death.

CFD is active against all clinically relevant GNBs, such as Enterobacteriaceae, *P. aeruginosa*, *Acinetobacter* spp.,




Figure 2 Diagnostic algorithm and positioning of new antimicrobials for the treatment of ventilator-associated pneumonia (VAP). ATB: antibiotic; BAL: bronchoalveolar lavage; BAS: bronchial aspirate; CPIS: clinical pulmonary infection rating scale; MDR: multidrug-resistant microorganisms; PCT: procalcitonin; CRP: C-reactive protein; PSB: protected brush; rt-PCR: polymerase chain reaction; CXR: chest X-ray; SIRS: systemic inflammatory response syndrome; CT: computed axial tomography.

as well as *Stenotrophomonas maltophilia*, yet ineffective against gram-positive cocci (GPCs) or anaerobes⁶¹⁻⁶³ (Fig. 1). The recommended dosages and comparative characteristics are outlined in Table 1. After a single dose of CFD, the half-life of the drug is similar to other β -lactams (2–2.7 h), with a volume of distribution of 16–18 l. However, protein binding is substantially higher (58%) than CTZ (11%–21%) and CAZ (21%),⁶⁴ and it is excreted essentially unchanged in urine (60%–90%). Its effect is time-dependent (%T > MIC) and elimination of more than 60% has been observed following a standard session of haemodialysis. Penetration into the lung is good, and in mechanically ventilated patients with VAP, the estimated alveolar fluid (ELF)/free plasma ratio was 0.21 by the end of the 2-g perfusion over 60 min and 0.55 two hours after perfusion was complete. ELF penetration was similar in both healthy subjects and ventilated patients, albeit with a decrease below the MIC for the most common microorganisms after 6 h; hence, dosing should take place between 4–6 h to maintain a%T > CIM greater than 50% between the dosing interval.

The APEKS-NP⁶⁵ study evaluated the non-inferiority of CFD versus MERO administered as a 3-h extended infusion in 300 patients with nosocomial pneumonia, including VAP, and despite the fact that this form of administration is not contemplated in the guidelines, it is the usual method of administration of MERO. No differences were observed in 14-day mortality (12.4% vs. 11.6%), nor in the frequency of clinical cure (65% vs. 67%) or microbiological eradication (41% vs. 42%) for CFD and MERO, respectively. Finally, the CREDIBLE-CR study was complementary to the previous studies, inasmuch as it examined CFD vs. MTD for the treatment of carbapenem-resistant GNB infections. The study included 150 patients (67 with NP) and no differences in clinical cure (43% vs. 43%) or microbiological eradication (30% vs. 29%) were recorded overall. Interestingly, mortality tended to be higher in CFD (34%) compared to MTD (18%, $P = .057$),

although none of the deaths were attributed to CFD. Given the broad spectrum of action on all BLEE, including MBL, CFD is an ATB that should be available in ICUs with a high frequency of intractable GNB.

Clinical considerations of the use of new antimicrobials in multi-resistance environments

Appropriate use of the new antimicrobials

The decision to use or reserve new ATBs is a challenging issue to face. It cannot be properly interpreted if it is not placed in a suitable global context that includes local epidemiology, the characteristics of the patient in particular, the focus of infection to be treated, and, of course, the implementation of antimicrobial optimisation programmes and treatment policies established by protocols agreed by consensus.⁶⁶ Furthermore, to facilitate the proper use of new antimicrobials, we believe that accurate and early microbiological information is essential. In this respect, modern techniques of early microbiological diagnosis by multiplex PCR⁶⁷ allow for early and targeted treatment, avoiding overuse of antimicrobials and reducing the selection pressure on the unit. Reserving new antimicrobials and administering alternative combinations of old antibiotics, which may have less of an effect or a higher incidence of side effects, does not appear to be the most appropriate option if rapid techniques are available to rule out the presence of multidrug-resistant microorganisms when choosing empirical or early targeted treatment. In Fig. 2, we suggest a diagnostic and treatment algorithm for ventilator-associated pneumonia that may be helpful to adapt in each ICU, depending on the local epidemiology.

Extended infusion

Continuous or extended perfusion of β -lactam antibiotics has demonstrated to improve the PK/PD conditions of β -lactams by maximising the time during which the plasma concentration remains above the MIC and increasing efficacy. Based on these considerations, modern combinations of β -lactams with an inhibitor should behave in a similar way. Little experience has been published concerning the use of new antimicrobials in extended perfusion. A recent study⁶⁸ illustrated that the standard dosing of 2 g every 8 h of CTZ/TAZ was sufficient to obtain plasma levels exceeding MIC ($fT > MIC$) more than 90% of the time, when microorganisms with a MIC < 6 mg/l were considered. However, only prolonged administration (4 h) or continuous infusion of CTZ/TAZ achieved target plasma levels in more than 90% of cases if the MIC of the microorganisms was ≥ 6 mg/l.⁶⁸ Treatment with a 4-h extended infusion of CAZ/AVI achieved a clinical cure rate of 80% and a microbiological cure rate of 90%.⁶⁹ In the same study, the authors used a daily dose of 10 g CAZ/AVI in 10 patients with severe *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* infections, achieving plasma levels of 63.6 mg/l, which correlated with high plasma levels/MIC ratio (median 13 mg/l) without evidence of neurological involvement or haematological toxicity.

The need to maintain consistently high plasma antimicrobial levels is a particularly relevant issue in critically ill patients, which is why, just as we are doing with other β -lactams, we recommend extended administration of CTZ/TAZ, especially in patients on mechanical ventilation or with increased creatinine clearance.

Conclusions

The rapid spread of extended-spectrum β -lactamase-producing strains, especially MBL, generally associated with the presence of Enterobacteriaceae or *P. aeruginosa*, has caused a very serious crisis in healthcare systems.

Increased population mobility, as well as the elevated prevalence of plasmid-mediated resistance emergence, or the high intestinal colonisation by MDR-GNB, contribute to this widespread and uncontrolled spread of resistance around the world.

The clinical importance of these infections is linked to their high mortality, especially since MBL-producing strains are usually resistant to all β -lactams, including new combinations of β -lactams or carbapenemics with β -lactamase inhibitors. In this dire context, the development of new combinations with modern and more potent β -lactamase inhibitors may restore sensitivity to classical ATBs to these treatment-resistant microorganisms. The clinical positioning of each is pending the results of their application in clinical trials in critically ill patients, or compassionate use if the best available treatments fail.

Funding

No funding has been received for this manuscript.

Conflict of interests

Alejandro Rodríguez has received fees from PFIZER, MSD, GILEAD, THERMOFISHER, ROCHE, and BIOMEREUX for his participation in educational activities.

The other remaining authors have no conflict of interests to declare.

References

- Saha M, Sarkar A. Review on multiple facets of drug resistance: a rising challenge in the 21st century. *J Xenobiot* [Internet]. 2021;11:197–214. Available from: <https://www.mdpi.com/2039-4713/11/4/13>
- Glen KA, Lamont IL. β -lactam resistance in *Pseudomonas aeruginosa*: current status, future prospects. *Pathogens* [Internet]. 2021;10:1638. Available from: <https://www.mdpi.com/2076-0817/10/12/1638>
- Sharma S, Barman P, Joshi S, Preet S, Saini A. Multidrug resistance crisis during COVID-19 pandemic: role of anti-microbial peptides as next-generation therapeutics. *Colloids Surf Biointerfaces* [Internet]. 2022;211:112303. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0927776521007499>
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18:268–81.
- Alkofide H, Alhammad AM, Alruwaili A, Aldemerdash A, Almangour TA, Alsuwayegh A, et al. Multidrug-resistant and extensively drug-resistant enterobacteriaceae: prevalence, treatments, and outcomes – a retrospective cohort study. *Infect Drug Resist*. 2020;13:4653–62.
- Gajdács M. The concept of an ideal antibiotic: implications for drug design. *Molecules*. 2019;24:892. <http://dx.doi.org/10.3390/molecules24050892>.
- Gajdács M, Bátor Z, Ábrók M, Lázár A, Burián K. Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. *Life*. 2020;10:16. <http://dx.doi.org/10.3390/life10020016>.
- Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983–2018. *JAMA*. 2020;323:164–76.
- Lyddiard D, Jones GL, Greatrex BW. Keeping it simple: lessons from the golden era of antibiotic discovery. *FEMS Microbiol Lett*. 2016;363:fnw084. <http://dx.doi.org/10.1093/femsle/fnw084>.
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48:1–12.
- Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J Infect Dis*. 2008;197:1079–81. <http://dx.doi.org/10.1086/533452>.
- Kostyanev T, Bonten MJM, O'Brien S, Steel H, Ross S, François B, et al. The innovative medicines initiative's. New drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. *J Antimicrob Chemother*. 2016;71:290–5.
- Agencia Española de Medicamentos y Productos Sanitarios. Informe de posicionamiento terapéutico de ceftazidima/avibactam (Zavicefta®) [Internet] [accessed 15 Jan 2022]. Available from: <https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-ceftazidima-avibactam-Zavicefta-antibioticos.pdf>.

14. Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. *Int J Antimicrobial Agents*. 2015;46:53–9.
15. Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. *Infect Dis Ther*. 2021;10:1989–2034.
16. Sebaaly J, Woods JA, Wargo KA. A review of ceftolozane/tazobactam for the treatment of infections caused by multidrug-resistant pathogens. *Infect Dis Clin Pract [Internet]*. 2018;26:198–203 [accessed 2022 Jan 16]. Available from: https://journals.lww.com/infectdis/Abstract/2018/07000/A_Review_of_Ceftolozane_Tazobactam_for_the_5.aspx
17. Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a pooled analysis of Phase 3 clinical trials. *J Antimicrobial Chemother*. 2017;72:268–72.
18. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). *Int J Antimicrobial Agents*. 2014;43:533–9.
19. Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2019;19:1299–311.
20. Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Diaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. *Crit Care*. 2020;24:383, <http://dx.doi.org/10.1186/s13054-020-03091-2>.
21. Fernández-Esgueva M, López-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, et al. Characterization of AmpC β -lactamase mutations of extensively drug-resistant *Pseudomonas aeruginosa* isolates that develop resistance to ceftolozane/tazobactam during therapy. *Enferm Infecc Microbiol Clin*. 2020;38:474–8, <http://dx.doi.org/10.1016/j.eimc.2020.01.017>.
22. Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious *Pseudomonas aeruginosa* infections: a multicentre nationwide clinical experience. *Int J Antimicrob Agents*. 2019;53:408–15, <http://dx.doi.org/10.1016/j.ijantimicag.2018.11.001>.
23. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane–tazobactam for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections: clinical effectiveness and evolution of resistance. *Clin Infect Dis*. 2017;65:110–20, <http://dx.doi.org/10.1093/cid/cix182>.
24. Novelli A, del Giacomo P, Rossolini GM, Tumbarello M. Meropenem/vaborbactam: a next generation β -lactam β -lactamase inhibitor combination. *Expert Rev Antimicrob Ther*. 2020;18:643–55, <http://dx.doi.org/10.1080/14787210.2020.1756775>.
25. Zhang HL, Cressman L, Lautenbach E. Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections. *J Glob Antimicrob Resist*. 2021;27:299–302, <http://dx.doi.org/10.1016/j.jgar.2021.09.015>.
26. Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, et al. Management of KPC-producing *Klebsiella pneumoniae* infections. *Clin Microbiol Infect*. 2018;24:133–44, <http://dx.doi.org/10.1016/j.cmi.2017.08.030>.
27. Hayden DA, White BP, Bennett KK. Review of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem/cilastatin-relebactam to target *Klebsiella pneumoniae* carbapenemase-producing enterobacterales. *J Pharm Technol*. 2020;36:202–10, <http://dx.doi.org/10.1177/8755122520934726>.
28. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and Safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. *Infect Dis Ther*. 2018;7:439–55, <http://dx.doi.org/10.1007/s40121-018-0214-1>.
29. Smith JR, Rybak JM, Claeys KC. Imipenem-cilastatin-relebactam: a novel β -lactam– β -lactamase inhibitor combination for the treatment of multidrug-resistant gram-negative infections. *Pharmacotherapy*. 2020;40:343–56.
30. Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher LW, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. *Clin Infect Dis*. 2020;70:1799–808, <http://dx.doi.org/10.1093/cid/ciz530>.
31. Heo YA. Imipenem/cilastatin/relebactam: a review in gram-negative bacterial infections. *Drugs*. 2021;81:377–88.
32. Mansour H, el Ouweini A, Chahine EB, Karaoui LR. Imipenem/cilastatin/relebactam: a new carbapenem β -lactamase inhibitor combination. *Am J Health Syst Pharm*. 2021;78:674–83, <http://dx.doi.org/10.1093/ajhp/zxab012>.
33. Fraile-Ribot PA, Zamorano L, Orellana R, del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of imipenem-relebactam against a large collection of *Pseudomonas aeruginosa* clinical isolates and isogenic-lactam-resistant mutants [Internet]; 2020, <http://dx.doi.org/10.1128/AAC.02165-19>.
34. Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, et al. A Randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). *Clin Infect Dis [Internet]*. 2021;73:e4539–48, <http://dx.doi.org/10.1093/cid/ciaa803>.
35. Monogue ML, Giovagnoli S, Bissantz C, Zampaloni C, Nicolau DP. In vivo efficacy of meropenem with a novel non-lactam–lactamase inhibitor, nacubactam, against gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model. *Antimicrobial Agents Chemother*. 2018;62:e02596–17, <http://dx.doi.org/10.1128/AAC.02596-17>.
36. Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing enterobacteriaceae. *J Antimicrobial Chemother*. 2019;74:953–60.
37. Barnes MD, Taracila MA, Good CE, Bajaksouzian S, Rojas LJ, van Duin D, et al. Nacubactam enhances meropenem activity against carbapenem-resistant *Klebsiella pneumoniae* producing KPC. *Antimicrobial Agents Chemother*. 2019;63:e00432–19, <http://dx.doi.org/10.1128/AAC.00432-19>.
38. Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP. Meropenem–nacubactam activity against AmpC-overproducing and KPC-expressing *Pseudomonas aeruginosa* in a neutropenic murine lung infection model. *Int J Antimicrobial Agents*. 2020;55:105838, <https://doi.org/10.1016/j.ijantimicag.2019.10.019>.
39. Mauri C, Maraolo AE, di Bella S, Luzzaro F, Principe L. The revival of aztreonam in combination with avibactam against metallo- β -lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases. *Antibiotics (Basel)*. 2021;10, <http://dx.doi.org/10.3390/antibiotics10081012>.

40. Xu T, Guo Y, Ji Y, Wang B, Zhou K. Epidemiology and mechanisms of ceftazidime-avibactam resistance in gram-negative bacteria. *Engineering*. 2021;138–45, <http://dx.doi.org/10.1016/j.eng.2020.11.004>.
41. Chew KL, Tay MKL, Cheng B, Lin RTP, Octavia S, Teo JWP. Aztreonam-avibactam combination restores susceptibility of aztreonam in dual-carbapenemase-producing enterobacteriaceae. *Antimicrobial Agents Chemother* [Internet]. 2018;62:e00414–8 [accessed 2022 Jan 27]. Available from: <https://doi.org/10.1128/AAC.00414-18>
42. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, et al. In Vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. *Antimicrobial Agents Chemother*. 2015;59:7842–6.
43. Esposito S, Stone GG, Papaparaskevas J. In vitro activity of aztreonam/avibactam against a global collection of *Klebsiella pneumoniae* collected from defined culture sources in 2016 and 2017. *J Global Antimicrobial Resistance*. 2021;24:14–22.
44. Bianco G, Boattini M, Comini S, Casale R, Iannaccone M, Cavallo R, et al. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacteriales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era. *Eur J Clin Microbiol Infect Dis* [Internet]. 2022;41:573–80, <http://dx.doi.org/10.1007/s10096-022-04408-5>.
45. Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK. WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of gram-negative bacteria collected worldwide in 2015. *Antimicrobial Agents Chemother*. 2017;61:e00072–17, <http://dx.doi.org/10.1128/AAC.00072-17>.
46. Thomson KS, Abdelghani S, Snyder JW, Thomson GK. Activity of cefepime-zidebactam against multidrug-resistant (Mdr) gram-negative pathogens. *Antibiotics*. 2019;8.
47. Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. *J Antimicrobial Chemother*. 2017;72:1373–85.
48. Khan Z, Iregui A, Landman D, Quale J. Activity of cefepime/zidebactam (WCK 5222) against *Enterobacteriaceae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* endemic to New York City medical centres. *J Antimicrobial Chemother*. 2019;74:2938–42.
49. Karlowsky JA, Hackel MA, Bouchillon SK, Sahn DF. In vitro activity of WCK 5222 (Cefepime-Zidebactam) against worldwide collected gram-negative bacilli not susceptible to carbapenems [Internet]; 2020. Available from: <https://doi.org/10.1128/AAC.01676-21>.
50. Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β -lactamases. *J Antimicrobial Chemother*. 2017;72:1696–703.
51. Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I, et al. Assessment of activity and resistance mechanisms to cefepime in combination with the novel β -lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing enterobacteriales. *Antimicrobial Agents Chemother*. 2022;66:e0167621, <http://dx.doi.org/10.1128/AAC.01676-21>.
52. Hamrick JC, Docquier J-D, Uehara T, Myers CL, Six DA, Chatwin CL, et al. VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-lactamases, restores activity of cefepime in enterobacteriales and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2020;64:e01963–2019, <http://dx.doi.org/10.1128/AAC.01963-19>.
53. Abdelraouf K, Almarzoky Abuhussain S, Nicolau DP. In vivo pharmacodynamics of new-generation β -lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine- β -lactamase-producing Gram-negative bacteria. *J Antimicrobial Chemother*. 2020;75:3601–10.
54. Kloezen W, Melchers RJ, Georgiou P-C, Mouton JW, Meletiadis J. Activity of cefepime in combination with the novel β -lactamase inhibitor taniborbactam (VNRX-5133) against extended-spectrum- β -lactamase-producing isolates in in vitro checkerboard assays. *Antimicrob Agents Chemother*. 2021;65:e02338–2420, <http://dx.doi.org/10.1128/AAC.02338-20>.
55. Tselepis L, Langley GW, Aboklaish AF, Widlake E, Jackson DE, Walsh TR, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. *Int J Antimicrobial Agents* [Internet]. 2020;56 [accessed 2022 Jan 31]. Available from: <https://doi.org/10.1016/j.ijantimicag.2020.10592>
56. Belley A, Huband MD, Fedler KA, Watters AA, Flamm RK, Shapiro S, et al. Development of broth microdilution MIC and disk diffusion. Antimicrobial susceptibility test quality control ranges for the combination of cefepime and the novel-lactamaseinhibitor enmetazobactam. *J Clin Microbiol* [Internet]. 2019;57:e00607–19 [accessed 2022 Jan 31]. Available from: <https://doi.org/10.1128/JCM.00607-19>
57. Papp-Wallace KM, Bethel CR, Caillon J, Barnes MD, Potel G, Bajaksouzian S, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent-lactam-lactamase inhibitor combination) released a global action plan to address. *Antimicrob Agents Chemother* [Internet]. 2019;63:e00105–00119 [accessed 2022 Jan 31]. Available from: <https://doi.org/10.1128/AAC.00105-19>
58. Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014–2015. *Antimicrobial Agents Chemother* [Internet]. 2019;63:e000514–000519 [accessed 2022 Jan 31]. Available from: <https://doi.org/10.1128/AAC.00514-19>
59. Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ. Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant gram-negative pathogens. *Pharmacotherapy*, Vol. 40. Pharmacotherapy Publications Inc.; 2020. p. 1228–47.
60. Jorda A, Zeitlinger M. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. *Expert Rev Clin Pharmacol*. 2021;14:777–91.
61. El-Lababidi RM, Rizk JG. Cefiderocol: a siderophore cephalosporin. *Annals of Pharmacotherapy*, Vol. 54. SAGE Publications Inc.; 2020. p. 1215–31.
62. Syed YY. Cefiderocol: a review in serious gram-negative bacterial infections. *Drugs*. 2021;81:1559–71.
63. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. *Drugs*, Vol. 79. Springer International Publishing; 2019. p. 271–89.
64. Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. *Expert Opin Invest Drugs*. 2018;27:193–7, <http://dx.doi.org/10.1080/13543784.2018.1426745>.
65. Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2021;21:213–25.
66. Yusuf E, Bax HI, Verkaik NJ, van Westreenen M. An update on eight “new” antibiotics against multidrug-

- resistant gram-negative bacteria. *J Clin Med*. 2021;10:1068, <http://dx.doi.org/10.3390/jcm10051068>.
67. Kamel NA, Alshahrani MY, Aboshanab KM, El Borhamy MI. Evaluation of the biofire filmarray pneumonia panel plus to the conventional diagnostic methods in determining the microbiological etiology of hospital-acquired pneumonia. *Biology (Basel)*. 2022;11:377, <http://dx.doi.org/10.3390/biology11030377>.
68. Pilmis B, Petitjean G, Lesprit P, Lafaurie M, El Helali N, Le Monnier A, et al. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis*. 2019;38:1457–61, <http://dx.doi.org/10.1007/s10096-019-03573-4>.
69. Goncette V, Layios N, Descy J, Fripiat F. Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study. *J Global Antimicrob Resist*. 2021;26:15–9, <http://dx.doi.org/10.1016/j.jgar.2021.04.015>.